The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 1, 2011, Pages 48-73

  Ou, Horng D ^a   May, Andrew P ^b   O'Shea, Clodagh C ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b FLUIDIGM CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VIRUSES;

DNA; VIRUS PROTEIN;

CHEMISTRY; GENETICS; HUMAN; METABOLISM; NEOPLASM; PROTEIN BINDING; REVIEW; VIROLOGY; VIRUS REPLICATION;

DNA; HUMANS; NEOPLASMS; PROTEIN BINDING; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 79953248134     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.88     Document Type: Article

References (221)

1. Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004, 5:101-113.
2. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70.
4. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
5. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, et al. A census of human cancer genes. Nat Rev Cancer 2004, 4:177-183.
6. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009, 458:719-724.
7. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M. T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 1982, 298:343-347.
8. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982, 297:474-478.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692.
10. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
11. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000, 406:378-382.
12. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278:261-263.
13. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17:43-52.
14. Eckhart W, Hutchinson MA, Hunter T. An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates. Cell 1979, 18:925-933.
15. Courtneidge SA, Smith AE. Polyoma virus transforming protein associates with the product of the c-src cellular gene. Nature 1983, 303:435-439.
16. Whyte P, Buchkovich KJ, Horowitz JM, Friend SH, Raybuck M, et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988, 334:124-129.
17. Kovesdi I, Reichel R, Nevins JR. Identification of a cellular transcription factor involved in E1A transactivation. Cell 1986, 45:219-228.
18. Whyte P, Williamson NM, Harlow E. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989, 56:67-75.
19. Eckner R, Ludlow JW, Lill NL, Oldread E, Arany Z, et al. Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996, 16:3454-3464.
20. Kaplan DR, Whitman M, Schaffhausen B, Pallas DC, White M, et al. Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity. Cell 1987, 50:1021-1029.
21. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2:331-341.
22. O'Shea CC. Viruses - seeking and destroying the tumor program. Oncogene 2005, 24:7640-7655.
23. O'Shea CC. DNA tumor viruses-the spies who lyse us. Curr Opin Genet Dev 2005, 15:18-26.
24. Lee SS, Glaunsinger B, Mantovani F, Banks L, Javier RT. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol 2000, 74:9680-9693.
25. Glaunsinger BA, Lee SS, Thomas M, Banks L, Javier R. Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene 2000, 19:5270-5280.
26. Lee SS, Weiss RS, Javier RT. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94:6670-6675.
27. Glaunsinger BA, Weiss RS, Lee SS, Javier R. Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2. EMBO J 2001, 20:5578-5586.
28. Latorre IJ, Roh MH, Frese KK, Weiss RS, Margolis B, et al. Viral oncoprotein-induced mislocalization of select PDZ proteins disrupts tight junctions and causes polarity defects in epithelial cells. J Cell Sci 2005, 118:4283-4293.
29. Hoppe A, Beech SJ, Dimmock J, Leppard KN. Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption. J Virol 2006, 80:3042-3049.
30. Yondola MA, Hearing P. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol 2007, 81:4264-4271.
31. Boyer J, Rohleder K, Ketner G. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 1999, 263:307-312.
32. Kleinberger T, Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J Virol 1993, 67:7556-7560.
33. Champagne C, Landry MC, Gingras MC, Lavoie JN. Activation of adenovirus type 2 early region 4 ORF4 cytoplasmic death function by direct binding to Src kinase domain. J Biol Chem 2004, 279:25905-25915.
34. Gingras MC, Champagne C, Roy M, Lavoie JN. Cytoplasmic death signal triggered by SRC-mediated phosphorylation of the adenovirus E4orf4 protein. Mol Cell Biol 2002, 22:41-56.
35. Maoz T, Koren R, Ben-Ari I, Kleinberger T. YND1 interacts with CDC55 and is a novel mediator of E4orf4-induced toxicity. J Biol Chem 2005, 280:41270-41277.
36. Estmer NilssonC, Petersen-Mahrt S, Durot C, Shtrichman R, Krainer AR, et al. The adenovirus E4-ORF4 splicing enhancer protein interacts with a subset of phosphorylated SR proteins. EMBO J 2001, 20:864-871.
37. Querido E, Marcellus RC, Lai A, Charbonneau R, Teodoro JG, et al. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirusinfected cells. J Virol 1997, 71:3788-3798.
38. Huang MM, Hearing P, et al. The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev 1989, 3:1699-1710.
39. Obert S, O'Connor RJ, Schmid S, Hearing P. The adenovirus E4-6/7 protein transactivates the E2 promoter by inducing dimerization of a heteromeric E2F complex. Mol Cell Biol 1994, 14:1333-1346.
40. Bandara LR, Lam EW, Sorensen TS, Zamanian M, Girling R, et al. DP-1: a cell cycle-regulated and phosphorylated component of transcription factor DRTF1/E2F which is functionally important for recognition by pRb and the adenovirus E4 orf 6/7 protein. EMBO J 1994, 13:3104-3114.
41. Hu QJ, Bautista C, Edwards GM, Defeo-Jones D, Jones RE, et al. Antibodies specific for the human retinoblastoma protein identify a family of related polypeptides. Mol Cell Biol 1991, 11:5792-5799.
42. Mayol X, Grana X, Baldi A, Sang N, Hu Q, et al. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain. Oncogene 1993, 8:2561-2566.
43. Giordano A, Whyte P, Harlow E, Franza BR Jr, Beach D, et al. A 60 kd cdc2-associated polypeptide complexes with the E1A proteins in adenovirus-infected cells. Cell 1989, 58:981-990.
44. Fax P, Lipinski KS, Esche H, Brockmann D. cAMPindependent activation of the adenovirus type 12 E2 promoter correlates with the recruitment of CREB-1/ATF-1, E1A(12S), and CBP to the E2-CRE. J Biol Chem 2000, 275:8911-8920.
45. Liu F, Green MR. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1a protein. Cell 1990, 61:1217-1224.
46. Scholer HR, Ciesiolka T, Gruss P. A nexus between Oct-4 and E1A: implications for gene regulation in embryonic stem cells. Cell 1991, 66:291-304.
47. Horikoshi N, Maguire K, Kralli A, Maldonado E, Reinberg D, et al. Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IID. Proc Natl Acad Sci U S A 1991, 88:5124-5128.
48. Giordano A, Lee JH, Scheppler JA, Herrmann C, Harlow E, et al. Cell cycle regulation of histone H1 kinase activity associated with the adenoviral protein E1A. Science New York, N.Y 1991, 253:1271-1275.
49. Boyd JM, Subramanian T, Schaeper U, La Regina M, Bayley S, et al. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J 1993, 12:469-478.
50. Taylor DA, Kraus VB, Schwarz JJ, Olson EN, Kraus WE. E1A-mediated inhibition of myogenesis correlates with a direct physical interaction of E1A12S and basic helix-loop-helix proteins. Mol Cell Biol 1993, 13:4714-4727.
51. Lewis BA, Tullis G, Seto E, Horikoshi N, Weinmann R, et al. Adenovirus E1A proteins interact with the cellular YY1 transcription factor. J Virol 1995, 69:1628-1636.
52. Folkers GE, van der Saag PT. Adenovirus E1A functions as a cofactor for retinoic acid receptor beta (RAR beta) through direct interaction with RAR beta. Mol Cell Biol 1995, 15:5868-5878.
53. Somasundaram K, Jayaraman G, Williams T, Moran E, Frisch S, et al. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Proc Natl Acad Sci U S A 1996, 93:3088-3093.
54. Reid JL, Bannister AJ, Zegerman P, Martinez-Balbas MA, Kouzarides T. E1A directly binds and regulates the P/CAF acetyltransferase. EMBO J 1998, 17:4469-4477.
55. Lipinski KS, Esche H, Brockmann D. Amino acids 1-29 of the adenovirus serotypes 12 and 2 E1A proteins interact with rap30 (TF(II)F) and TBP in vitro. Virus Res 1998, 54:99-106.
56. Mazzarelli JM, Mengus G, Davidson I, Ricciardi RP. The transactivation domain of adenovirus E1A interacts with the C terminus of human TAF(II)135. J Virol 1997, 71:7978-7983.
57. Boyer TG, Martin ME, Lees E, Ricciardi RP, Berk AJ. Mammalian Srb/Mediator complex is targeted by adenovirus E1A protein. Nature 1999, 399:276-279.
58. Look DC, Roswit WT, Frick AG, Gris-Alevy Y, Dickhaus DM, et al. Direct suppression of Stat1 function during adenoviral infection. Immunity 1998, 9:871-880.
59. Nishihara A, Hanai J, Imamura T, Miyazono K, Kawabata M. E1A inhibits transforming growth factor-beta signaling through binding to Smad proteins. J Biol Chem 1999, 274:28716-28723.
60. Hateboer G, Gennissen A, Ramos YF, Kerkhoven RM, Sonntag-Buck V, et al. BS69, a novel adenovirus E1A-associated protein that inhibits E1A transactivation. EMBO J 1995, 14:3159-3169.
61. Turnell AS, Grand RJ, Gorbea C, Zhang X, Wang W, et al. Regulation of the 26S proteasome by adenovirus E1A. EMBO J 2000, 19:4759-4773.
62. Zhang X, Turnell AS, Gorbea C, Mymryk JS, Gallimore PH, et al. The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J Biol Chem 2004, 279:25122-25133.
63. Ansieau S, Strobl LJ, Leutz A. Activation of the Notch-regulated transcription factor CBF1/RBPJkappa through the 13 SE1A oncoprotein. Genes Dev 2001, 15:380-385.
64. Fax P, Carlson CR, Collas P, Tasken K, Esche H, et al. Binding of PKA-RIIalpha to the Adenovirus E1A12S oncoprotein correlates with its nuclear translocation and an increase in PKA-dependent promoter activity. Virology 2001, 285:30-41.
65. Sang N, Severino A, Russo P, Baldi A, Giordano A, et al. RACK1 interacts with E1A and rescues E1Ainduced yeast growth inhibition and mammalian cell apoptosis. J Biol Chem2001, 276:27026-27033.
66. Fuchs M, Gerber J, Drapkin R, Sif S, Ikura T, et al. The p400 complex is an essential E1A transformation target. Cell 2001, 106:297-307.
67. Xin H, D'Souza S, Fang L, Lengyel P, Choubey D. p202, an interferon-inducible negative regulator of cell growth, is a target of the adenovirus E1A protein. Oncogene 2001, 20:6828-6839.
68. Lang SE, Hearing P. The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene 2003, 22:2836-2841.
69. Cha EJ, Oh BC, Wee HJ, Chi XZ, Goh YM, et al. E1A physically interacts with RUNX3 and inhibits its transactivation activity. J Cell Biochem 2008, 105:236-244.
70. Hateboer G, Hijmans EM, Nooij JB, Schlenker S, Jentsch S, et al. mUBC9, a novel adenovirus E1Ainteracting protein that complements a yeast cell cycle defect. J Biol Chem 1996, 271:25906-25911.
71. Han J, Sabbatini P, Perez D, Rao L, Modha D, et al. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 1996, 10:461-477.
72. Farrow SN, White JH, Martinou I, Raven T, Pun KT, et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995, 374:731-733.
73. Yasuda M, Theodorakis P, Subramanian T, Chinnadurai G. Adenovirus E1B-19K/BCL-2 interacting protein BNIP3 contains a BH3 domain and a mitochondrial targeting sequence. J Biol Chem 1998, 273:12415-12421.
74. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol 1996, 16:5857-5864.
75. Kasof GM, Goyal L, White E. Btf, a novel deathpromoting transcriptional repressor that interacts with Bcl-2-related proteins. Mol Cell Biol 1999, 19:4390-4404.
76. Rao L, Modha D, White E. The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis. Oncogene 1997, 15:1587-1597.
77. Kao CC, Yew PR, Berk AJ. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990, 179:806-814.
78. Punga T, Akusjarvi G. The adenovirus-2 E1B-55K protein interacts with a mSin3A/histone deacetylase 1 complex. FEBS Lett 2000, 476:248-252.
79. Liu Y, Shevchenko A, Berk AJ. Adenovirus exploits the cellular aggresome response to accelerate inactivation of the MRN complex. J Virol 2005, 79:14004-14016.
80. Baker A, Rohleder KJ, Hanakahi LA, Ketner G. Adenovirus E4 34k and E1b 55k oncoproteins target host DNA ligase IV for proteasomal degradation. J Virol 2007, 81:7034-7040.
81. Gabler S, Schutt H, Groitl P, Wolf H, Shenk T, et al. E1B 55-kilodalton-associated protein: a cellular protein with RNA-binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs. J Virol 1998, 72:7960-7971.
82. Harada JN, Shevchenko A, Pallas DC, Berk AJ. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 2002, 76:9194-9206.
83. Kiyono T, Hiraiwa A, Fujita M, Hayashi Y, Akiyama T, et al. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein. Proc Natl Acad Sci U S A 1997, 94:11612-11616.
84. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993, 13:775-784.
85. Crook T, Tidy JA, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 1991, 67:547-556.
86. Chen JJ, Hong Y, Rustamzadeh E, Baleja JD, Androphy EJ. Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 1998, 273:13537-13544.
87. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12:2061-2072.
88. Tong X, Howley PM. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton. Proc Natl Acad Sci U S A 1997, 94:4412-4417.
89. Jing M, Bohl J, Brimer N, Kinter M, Vande Pol SB. Degradation of tyrosine phosphatase PTPN3 (PTPH1) by association with oncogenic human papillomavirus E6 proteins. J Virol 2007, 81:2231-2239.
90. Degenhardt YY, Silverstein SJ. Gps2, a protein partner for human papillomavirus E6 proteins. J Virol 2001, 75:151-160.
91. Degenhardt YY, Silverstein S. Interaction of zyxin, a focal adhesion protein, with the e6 protein from human papillomavirus type 6 results in its nuclear translocation. J Virol 2001, 75:11791-11802.
92. Filippova M, Johnson MM, Bautista M, Filippov V, Fodor N, et al. The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 2007, 81:4116-4129.
93. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999, 18:5061-5072.
94. Thomas M, Banks L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 1998, 17:2943-2954.
95. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem 2004, 279:25729-25744.
96. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem 2002, 277:21730-21739.
97. Kumar A, Zhao Y, Meng G, Zeng M, Srinivasan S, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 2002, 22:5801-5812.
98. Lu Z, Hu X, Li Y, Zheng L, Zhou Y, et al. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004, 279:35664-35670.
99. Gao Q, Kumar A, Singh L, Huibregtse JM, Beaudenon S, et al. Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 2002, 62:3315-3321.
100. Kuhne C, Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 1998, 273:34302-34309.
101. Iftner T, Elbel M, Schopp B, Hiller T, Loizou JI, et al. Interference of papillomavirus E6 protein with singlestrand break repair by interaction with XRCC1. EMBO J 2002, 21:4741-4748.
102. Nakagawa S, Huibregtse JM. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol 2000, 20:8244-8253.
103. Gao Q, Kumar A, Srinivasan S, Singh L, Mukai H, et al. PKN binds and phosphorylates human papillomavirus E6 oncoprotein. J Biol Chem 2000, 275:14824-14830.
104. Li S, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AH, et al. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha. Oncogene 1999, 18:5727-5737.
105. Zhang Y, Fan S, Meng Q, Ma Y, Katiyar P, et al. BRCA1 interaction with human papillomavirus oncoproteins. J Biol Chem2005, 280:33165-33177.
106. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science New York, NY 1989, 243:934-937.
107. Dyson N, Guida P, Munger K, Harlow E. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteinsmediate interactionwith the same set of cellular proteins. J Virol 1992, 66:6893-6902.
108. Funk JO, Waga S, Harry JB, Espling E, Stillman B, et al. Inhibition ofCDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev 1997, 11:2090-2100.
109. Thomas M, Matlashewski G, Pim D, Banks L, et al. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996, 13:265-273.
110. Tommasino M, Adamczewski JP, Carlotti F, Barth CF, Manetti R, et al. HPV16 E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene 1993, 8:195-202.
111. Nguyen CL, Munger K. Direct association of the HPV16 E7 oncoprotein with cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 2008, 380:21-25.
112. McLaughlin-Drubin ME, Huh KW, Munger K. Human papillomavirus type 16 E7 oncoprotein associates with E2F6. J Virol 2008, 82:8695-8705.
113. Brehm A, Nielsen SJ, Miska EA, McCance DJ, Reid JL, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999, 18:2449-2458.
114. Avvakumov N, Torchia J, Mymryk JS. Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 2003, 22:3833-3841.
115. Bernat A, Avvakumov N, Mymryk JS, Banks L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003, 22:7871-7881.
116. Huh KW, DeMasi J, Ogawa H, Nakatani Y, Howley PM, et al. Association of the human papillomavirus type 16 E7 oncoprotein with the 600-kDa retinoblastoma protein-associated factor, p600. Proc Natl Acad Sci U S A 2005, 102:11492-11497.
117. Zwerschke W, Mannhardt B, Massimi P, Nauenburg S, Pim D, et al. Allosteric activation of acid alphaglucosidase by the human papillomavirus E7 protein. J Biol Chem 2000, 275:9534-9541.
118. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, et al. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A 1999, 96:1291-1296.
119. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, et al. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol 2000, 20:6483-6495.
120. Barnard P, McMillan NA. The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. Virology 1999, 259:305-313.
121. Prathapam T, Kuhne C, Banks L. The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene 2001, 20:7677-7685.
122. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein; implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000, 275:6764-6769.
123. Wang YW, Chang HS, Lin CH, Yu WC. HPV-18 E7 conjugates to c-Myc and mediates its transcriptional activity. Int J Biochem Cell Biol 2007, 39:402-412.
124. Massimi P, Pim D, Storey A, Banks L. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene 1996, 12:2325-2330.
125. Berezutskaya E, Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997, 272:30135-30140.
126. Schilling B, De-Medina T, Syken J, Vidal M, Munger K. A novel human DnaJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Virology 1998, 247:74-85.
127. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005, 24:7830-7838.
128. DeCaprio JA, Ludlow JW, Figge J, Shew JY, Huang CM, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988, 54:275-283.
129. Ewen ME, Xing YG, Lawrence JB, Livingston DM. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 1991, 66:1155-1164.
130. Hannon GJ, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins. Genes Dev 1993, 7:2378-2391.
131. Adamczewski JP, Gannon JV, Hunt T. Simian virus 40 large T antigen associates with cyclin A and p33cdk2. J Virol 1993, 67:6551-6557.
132. Sullivan CS, Gilbert SP, Pipas JM. ATP-dependent simian virus 40 T-antigen-Hsc70 complex formation. J Virol 2001, 75:1601-1610.
133. Ali SH, Kasper JS, Arai T, DeCaprio JA. Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004, 78:2749-2757.
134. Cotsiki M, Lock RL, Cheng Y, Williams GL, Zhao J, et al. Simian virus 40 large T antigen targets the spindle assembly checkpoint protein Bub1. Proc Natl Acad Sci U S A 2004, 101:947-952.
135. Berger LC, Smith DB, Davidson I, Hwang JJ, Fanning E, et al. Interaction between T antigen and TEA domain of the factor TEF-1 derepresses simian virus 40 late promoter in vitro: identification of T-antigen domains important for transcription control. J Virol 1996, 70:1203-1212.
136. Wu X, Avni D, Chiba T, Yan F, Zhao Q, et al. SV40 T antigen interacts with Nbs1 to disrupt DNA replication control. Genes Dev 2004, 18:1305-1316.
137. Welcker M, Clurman BE. The SV40 large T antigen contains a decoy phosphodegron that mediates its interactions with Fbw7/hCdc4. J Biol Chem2005, 280:7654-7658.
138. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 1990, 60:167-176.
139. Pallas DC, Cherington V, Morgan W, DeAnda J, Kaplan D, et al. Cellular proteins that associate with the middle and small T antigens of polyomavirus. J Virol 1988, 62:3934-3940.
140. Courtneidge SA, Smith AE. The complex of polyoma virus middle-T antigen and pp60c-src. EMBO J 1984, 3:585-591.
141. Courtneidge SA, Heber A. An 81 kd protein complexed with middle T antigen and pp60c-src: a possible phosphatidylinositol kinase. Cell 1987, 50:1031-1037.
142. Tian Y, Li D, Dahl J, You J, Benjamin T. Identification of TAZ as a binding partner of the polyomavirus T antigens. J Virol 2004, 78:12657-12664.
143. Su W, Liu W, Schaffhausen BS, Roberts TM. Association of Polyomavirus middle tumor antigen with phospholipase C-gamma 1. J Biol Chem 1995, 270:12331-12334.
144. Pallas DC, Fu H, Haehnel LC, Weller W, Collier RJ, et al. Association of polyomavirus middle tumor antigen with 14-3-3 proteins. Science New York, NY 1994, 265:535-537.
145. Dilworth SM, Brewster CE, Jones MD, Lanfrancone L, Pelicci G, et al. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature 1994, 367:87-90.
146. Cheng SH, Espino PC, Marshall J, Harvey R, Merrill J, et al. Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen. J Virol 1991, 65:170-179.
147. Kornbluth S, Sudol M, Hanafusa H. Association of the polyomavirusmiddle-T antigen with c-yes protein. Nature 1987, 325:171-173.
148. Li Y, Kang J, Horwitz MS. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers. J Virol 1997, 71:1576-1582.
149. Li Y, Kang J, Horwitz MS. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol 1998, 18:1601-1610.
150. Li Y, Kang J, Friedman J, Tarassishin L, Ye J, et al. Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alphainduced apoptosis. Proc Natl Acad Sci U S A 1999, 96:1042-1047.
151. Chen P, Tian J, Kovesdi I, Bruder JT. Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem 1998, 273:5815-5820.
152. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 1985, 41:987-997.
153. Liu H, Fu J, Bouvier M. Allele- and locus-specific recognition of class I MHC molecules by the immunomodulatory E3-19K protein from adenovirus. J Immunol 2007, 178:4567-4575.
154. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has twomechanisms for affecting class I MHC expression. J Immunol 1999, 162:5049-5052.
155. Dilworth SM. Cell alterations induced by the large T-antigens of SV40 and polyoma virus. Semin Cancer Biol 1990, 1:407-414.
156. Moule MG, Collins CH, McCormick F, Fried M. Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A 2004, 101:14063-14066.
157. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene 2005, 24:7746-7755.
158. O'Shea C, Klupsch K, Choi S, Bagus B, Soria C, et al. Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J 2005, 24:1211-1221.
159. O'Shea CC, Choi S, McCormick F, Stokoe D. Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle 2005, 7:883-888.
160. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science New York, NY 1998, 282:284-287.
161. Finlay BB, McFadden G. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 2006, 124:767-782.
162. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
163. Rosa F, Berissi H, Weissenbach J, Maroteaux L, Fellous M, et al. The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J 1983, 2:239-243.
164. Horton TM, Ranheim TS, Aquino L, Kusher DI, Saha SK, et al. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol 1991, 65:2629-2639.
165. Tollefson AE, Hermiston TW, Lichtenstein DL, Colle CF, Tripp RA, et al. Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 1998, 392:726-730.
166. Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, et al. Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol 2001, 75:8875-8887.
167. Lee SH, Shin MS, Kim HS, Park WS, Kim SY, et al. Somatic mutations of Fas (Apo-1/CD95) gene in cutaneous squamous cell carcinoma arising from a burn scar. J Invest Dermatol 2000, 114:122-126.
168. Pai SI, Wu GS, Ozoren N, Wu L, Jen J, et al. Rare lossof-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58:3513-3518.
169. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009, 9:778-788.
170. Rothwarf DM, Zandi E, Natoli G, Karin M. IKKgamma is an essential regulatory subunit of the IkappaB kinase complex. Nature 1998, 395:297-300.
171. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
172. Kalvakolanu DV, Bandyopadhyay SK, Harter ML, Sen GC. Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation. Proc Natl Acad Sci U S A 1991, 88:7459-7463.
173. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, et al. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proc Natl Acad Sci U S A 1996, 93:15092-15096.
174. Cattaneo R, Miest T, Shashkova EV, Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6:529-540.
175. Borden EC, Lindner D, Dreicer R, Hussein M, Peereboom D. Second-generation interferons for cancer: clinical targets. Semin Cancer Biol 2000, 10:125-144.
176. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985, 250-257.
177. Russell WC. Update on adenovirus and its vectors. J Gen Virol 2000, 81:2573-2604.
178. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, et al. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol 1999, 17:1030-1032.
179. Puig O, Caspary F, Rigaut G, Rutz B, Bouveret E, et al. The tandem affinity purification (TAP) method: a general procedure of protein complex purification. Methods 2001, 24:218-229.
180. Gavin AC, Bosche M, Krause R, Grandi P, Marzioch M, et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 2002, 415:141-147.
181. Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science New York, NY 2007, 316:1043-1046.
182. Junttila MR, Saarinen S, Schmidt T, Kast J, Westermarck J. Single-step Strep-tag purification for the isolation and identification of protein complexes from mammalian cells. Proteomics 2005, 5:1199-1203.
183. Tackett AJ, DeGrasse JA, Sekedat MD, Oeffinger M, Rout MP, et al. I-DIRT, a general method for distinguishing between specific and nonspecific protein interactions. J Proteome Res 2005, 4:1752-1756.
184. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, et al. Global analysis of protein activities using proteome chips. Science New York, NY 2001, 293:2101-2105.
185. Stracker TH, Carson CT, Weitzman MD. Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 2002, 418:348-352.
186. O'Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cells 2005, 8:61-74.
187. Ptacek J, Devgan G, Michaud G, Zhu H, Zhu X, et al. Global analysis of protein phosphorylation in yeast. Nature 2005, 438:679-684.
188. Gupta R, Kus B, Fladd C, Wasmuth J, Tonikian R, et al. Ubiquitination screen using protein microarrays for comprehensive identification of Rsp5 substrates in yeast. Mol Syst Biol 2007, 3:116.
189. Boyle SN, Michaud GA, Schweitzer B, Predki PF, Koleske AJ. A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsalwave formation. Curr Biol 2007, 17:445-451.
190. Iacovides DC, O'Shea CC, Oses-Prieto J, Burlingame A, McCormick F. Critical role for arginine methylation in adenovirus-infected cells. J Virol 2007, 81:13209-13217.
191. DeCaprio JA. How the Rb tumor suppressor structure and function was revealed by the study of Adenovirus and SV40. Virology 2009, 384:274-284.
192. Pelka P, Ablack JN, Fonseca GJ, Yousef AF, Mymryk JS. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J Virol 2008, 82:7252-7263.
193. Lee JO, Russo AA, Pavletich NP. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 1998, 391:859-865.
194. Jones RE, Wegrzyn RJ, Patrick DR, Balishin NL, Vuocolo GA, et al. Identification of HPV-16 E7 peptides that are potent antagonists of E7 binding to the retinoblastoma suppressor protein. J Biol Chem1990, 265:12782-12785.
195. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-and-neck cancer. Nat Clin Pract Oncol 2008, 5:24-31.
196. Heck DV, Yee CL, Howley PM, Munger K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc Natl Acad Sci U S A 1992, 89:4442-4446.
197. Baneyx F, Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol 2004, 22:1399-1408.
198. Hosfield D, Palan J, Hilgers M, Scheibe D, McRee DE, et al. A fully integrated protein crystallization platform for small-molecule drug discovery. J Struct Biol 2003, 142:207-217.
199. Hansen CL, Skordalakes E, Berger JM, Quake SR. A robust and scalable microfluidic metering method that allows protein crystal growth by free interface diffusion. Proc Natl Acad Sci U S A 2002, 99:16531-16536.
200. Endo Y, Sawasaki T. High-throughput, genome-scale protein production method based on the wheat germ cell-free expression system. Biotechnol Adv 2003, 21:695-713.
201. Li C, Schwabe JW, Banayo E, Evans RM. Coexpression of nuclear receptor partners increases their solubility and biological activities. Proc Natl Acad Sci U S A 1997, 94:2278-2283.
202. Held D, Yeager K, Novy R. New co-expression vectors for expanded compatibilities in E. coli. Innovations 2003, 18:4-6.
203. Michnick SW, Ear PH, Manderson EN, Remy I, Stefan E. Universal strategies in research and drug discovery based on protein-fragment complementation assays. Nat Rev 2007, 6:569-582.
204. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, et al. Structural basis of PP2A inhibition by small t antigen. PLoS Biol 2007, 5:e202.
205. Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes Dev 2006, 20:2373-2382.
206. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9:402-412.
207. Joo WS, Jeffrey PD, Cantor SB, Finnin MS, Livingston DM, et al. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. Genes Dev 2002, 16:583-593.
208. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002, 8:282-288.
209. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008, 20:90-96.
210. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683.
211. Dunker AK, Cortese MS, Romero P, Iakoucheva LM, Uversky VN. Flexible nets: the roles of intrinsic disorder in protein interaction networks. FEBS J 2005, 272:5129-5148.
212. Reeves R. Molecular biology ofHMGAproteins: hubs of nuclear function. Gene 2001, 277:63-81.
213. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol 1999, 293:321-331.
214. Ferreon JC, Martinez-Yamout MA, Dyson HJ, Wright PE. Structural basis for subversion of cellular control mechanisms by the adenoviral E1A oncoprotein. Proc Natl Acad Sci U S A 2009, 106:13260-13265.
215. Gu W, Shi XL, Roeder RG. Synergistic activation of transcription by CBP and p53. Nature 1997, 387:819-823.
216. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387:823-827.
217. O'Connor MJ, Zimmermann H, Nielsen S, Bernard HU, Kouzarides T. Characterization of an E1ACBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. J Virol 1999, 73:3574-3581.
218. Stein RW, Corrigan M, Yaciuk P, Whelan J, Moran E. Analysis of E1A-mediated growth regulation functions: binding of the 300-kilodalton cellular product correlates with E1A enhancer repression function and DNA synthesis-inducing activity. J Virol 1990, 64:4421-4427.
219. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, et al. Epigenetic reprogramming by adenovirus e1a. Science New York, NY 2008, 321:1086-1088.
220. Batada NN, Hurst LD, Tyers M. Evolutionary and physiological importance of hub proteins. PLoS Comput Biol 2006, 2:e88.
221. Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, et al. Sequence complexity of disordered protein. Proteins 2001, 42:38-48.